Roche closes insulin pump co Medingo

Roche acquired Medingo for $200 million in 2010. More than 100 jobs will be shed at the company's Yokne'am plant.

Roche AG's (SWX: ROG) Diagnostics Division is due to close Medingo, two years after acquiring the miniature insulin pump developer for $200 million. Medingo produces its insulin pumps at its facility in Yokne'am, which has more than 100 employees.

Sources inform ''Globes'' that Roche Diagnostics is transferring its Israeli insulin pumps R&D activity to Europe in order to consolidate it with the company's diabetes operations. The move is part of a massive restructuring by Roche. Most of Medingo's development staff have been offered relocation at the new facility, but most of them will probably seek work in Israel's medical devices industry.

The closing of Medingo is not a big surprise. Roche acquired the company when it did not yet have a product, and the establishment of the Israeli facility is easy to relocate. Roche was mostly interested in Medingo's technology, and it was obvious from the outset that it would set up a production facility in a low-cost location, and transfer marketing operations to the US or Europe, where the markets are. Israel's development capabilities were unable to tip the scales against Roche's need to cut costs.

Medingo's product is due to reach markets in a few months, after a short delay. If it achieves strong sales, its sellers - IDB Holding Corp. Ltd. (TASE:IDBH) unit Elron Electronic Industries Ltd. (TASE: ELRN) and Rafael Development Corporation could reap revenue from royalties payments.

Published by Globes [online], Israel business news - - on January 22, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Twitter Facebook Linkedin RSS Newsletters גלובס Capital  Markets Conference 2017